ReviewInternational orthopaedics2014
The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing.
Review in International orthopaedics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Bone morphogenetic protein in adult spinal deformity surgery: a meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2017Pooled it
- Recombinant Human BMP6 Applied Within Autologous Blood Coagulum Accelerates Bone Healing: Randomized Controlled Trial in High Tibial Osteotomy Patients.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020Trial
- Bone Induction as a Function of Size and Chemical Composition of Calcium Phosphate Granules in Osteogrow-C Evaluated in Animal Models: A 1-Year Follow-Up.Biomaterials research · 2026Article
- BMP3 Deficiency Accelerates Cartilage-to-Bone Transition in Ectopic Bone.Biomedicines · 2025Article
- Time to consider fracture nonunion an orphan disease? An update into pathophysiology, epidemiology and therapeutic solutions.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2025Review
- Regeneration of Chronic Alveolar Vertical Defects Using a Micro Dosage of rhBMP-2. An Experimental In Vivo Study.Clinical oral implants research · 2025Article
- Emerging Strategies for Bioactive Agent-Loaded Xenogeneic Bone Scaffolds in Regenerative Medicine: A Comprehensive Review.Drug design, development and therapy · 2025Review
- Systemic inhibition of bone morphogenetic protein 1.3 as a possible treatment for laminin-related congenital muscular dystrophy.International orthopaedics · 2025Review
- Regeneration of a Rabbit Segmental Defect with a New Bone Therapy: Autologous Blood Coagulum with Bone Morphogenetic Protein 6 and Synthetic Ceramics.Biomaterials research · 2025Article
- Impact of Cerium Doping on the Osteogenic Properties of a 3D Biomimetic Piezoelectric Scaffold with Sustained MgInternational journal of nanomedicine · 2025Article
- Peptide Hydrogel for Sustained Release of Recombinant Human Bone Morphogenetic Protein-2 In Vitro.Journal of functional biomaterials · 2024Article
- Article
- Mesenchymal Stem Cells Cultured in a 3D Microgel Environment Containing Platelet-Rich Plasma Significantly Modify Their Chondrogenesis-Related miRNA Expression.International journal of molecular sciences · 2024Article
- Calcium phosphate ceramics combined with rhBMP6 within autologous blood coagulum promote posterolateral lumbar fusion in sheep.Scientific reports · 2023Article
- Complications of Percutaneous Vertebroplasty: A Pictorial Review.Medicina (Kaunas, Lithuania) · 2023Review
- Role and Mechanism of BMP4 in Regenerative Medicine and Tissue Engineering.Annals of biomedical engineering · 2023Review
- A Mixture ofInternational journal of molecular sciences · 2023Article
- Bone morphogenetic protein signaling is a possible therapeutic target in gynecologic cancer.Cancer science · 2023Review
- Activin receptor-like kinase 3: a critical modulator of development and function of mineralized tissues.Frontiers in cell and developmental biology · 2023Review
- Comparison of synthetic ceramic products formulated with autologous blood coagulum containing rhBMP6 for induction of bone formation.International orthopaedics · 2022Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to revise the clinical use of commercial BMP2 (Infuse) and BMP7 (Osigraft) based bone devices and explore the mechanism of action and efficacy of low BMP6 doses in a novel whole blood biocompatible device OSTEOGROW.
methodsComplications from the clinical use of BMP2 and BMP7 have been systemically reviewed in light of their role in bone remodeling. BMP6 function has been assessed in Bmp6-/- mice by μCT and skeletal histology, and has also been examined in mesenchymal stem cells (MSC), hematopoietic stem cells (HSC) and osteoclasts. Safety and efficacy of OSTEOGROW have been assessed in rats and rabbits.
resultsClinical use issues of BMP2 and BMP7 have been ascribed to the limited understanding of their role in bone remodeling at the time of device development for clinical trials. BMP2 and BMP7 in bone devices significantly promote bone resorption leading to osteolysis at the endosteal surfaces, while in parallel stimulating exuberant bone formation in surrounding tissues. Unbound BMP2 and BMP7 in bone devices precipitate on the bovine collagen and cause inflammation and swelling. OSTEOGROW required small amounts of BMP6, applied in a biocompatible blood coagulum carrier, for stimulating differentiation of MSCs and accelerated healing of critical size bone defects in animals, without bone resorption and inflammation. BMP6 decreased the number of osteoclasts derived from HSC, while BMP2 and BMP7 increased their number.
conclusionsCurrent issues and challenges with commercial bone devices may be resolved by using novel BMP6 biocompatible device OSTEOGROW, which will be clinically tested in metaphyseal bone fractures, compartments where BMP2 and BMP7 have not been effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.